Overview

Efficacy Study of Pneumococcal Vaccination in Crohn's Disease

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
A growing number of patients with Crohn's disease are treated with immunosuppressive agents, such as anti-tumor necrosis factor blockers and immunomodulators. Several recent studies have indicated that immunosuppressive treatment may impair the immunological response to pneumococcal vaccination in patients with inflammatory bowel disease (Crohn's disease and Ulcerative colitis). One of weaknesses in the previous studies did not focus on specific disease, such as Crohn's disease. In addition, predictive factors affecting impaired response following pneumococcal vaccination have not clearly evaluated in patients with Crohn's disease. In this study, patients with Crohn's disease will be assessed for serological response to pneumococcal vaccination. Further, potential predictive factors that impact on vaccination outcomes and adverse events related to vaccination will be evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
Kyunghee University Medical Center
Collaborators:
Asan Medical Center
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Ewha Womans University
Inje University
Keimyung University Dongsan Medical Center
Konkuk University Hospital
Korea University
Kosin University Gospel Hospital
Seoul National University Hospital
Severance Hospital
Soonchunhyang University Hospital
The Catholic University of Korea
Wonju Severance Christian Hospital
Wonkwang University
Treatments:
Adjuvants, Immunologic
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Vaccines